predictive biomarker for clinical efficacy of immune checkpoint inhibitors (ICIs). There is a lack of standardization for TMB estimation and reporting, which is critical for ensuring consistency for clinical implementation. An international collaboration organized by Friends of Cancer Research (Friends) and Qualitätssicherungs-Initiative Pathologie GmbH (QuIP) is establishing recommendations for achieving consistency in TMB estimation and reporting. Method: Friends and QuIP are using complementary TMB harmonization approaches. Friends will conduct in silico analyses where TCGA data will be compared between TMB estimates derived from whole exome sequencing (WES) and commercial targeted gene panels, followed by the use of patientderived tumor cell lines to establish a universal reference standard for the alignment of panel-derived estimates. QuIP will compare TMB estimates from selected tissue (NSCLC and other solid tumors) using a WES-derived reference standard with commercial next-generation sequencing panels and lab-developed tests at several German academic institutions. These data will inform consistency of TMB estimation, assay comparability, and TMB cutoff values for potential clinical use. Results: Preliminary data indicate several components influence TMB estimation: preanalytical factors (eg, input material quality/quantity), sequencing parameters (eg, enrichment technologies), library preparation, bioinformatics (eg, filtering of germline variants), FFPE-induced deamination artifacts, mutation types, and clonal vs subclonal events. Analyses of panel size and composition suggest that larger panels may yield more reliable TMB estimation and that the panel should include actionable targets, genes associated with mutagenesis (eg, microsatellite instability), and potential negative predictors of response (eg, mutated b2M, JAK1/2, PTEN Burning Rock Biotech, Guangzhou/CN Background: Human epidermal growth factor 2 (HER2, ERBB2) gene alterations have been identified as oncogenic drivers in 2-5% of lung cancers. ERBB2 In-frame insertions in exon 20 (20ins) lead to constitutive activation of receptor and downstream pathways. However, response heterogeneity of different exon 20 insertions to ERBB2 inhibitor afatinib exists. In vitro and structural modeling results suggested that Glycine778 may facilitate inhibitor binding to ERBB2. In this study, our aim was to improve our understanding of clinical characteristics in ERBB2-mutated Chinese lung cancer and investigate the clinical outcomes of specific ERBB2 exon 20 insertions in response to afatinib. Method: We reviewed 7520 lung cancer patients whose tissue or plasma biopsies were sequenced in a CLIA-certified sequencing laboratory between 2015 to 2018. Clinical records of 19 patients (18 adenocarcinomas and 1 squamous cell carcinoma) with several different ERBB2 20ins after afatinib treatment were collected for clinical outcomes evaluation. Results: ERBB2 20ins were identified in 2.27% (171/7,520) in this Chinese lung cancer cohort. It occurred with a high proportion in females with adenocarcinoma histology. 11.7% (20/171) ERBB2 20ins-positive patients harbored concomitant ERBB2 amplification. Y772_A775dup (119/171, 69.6%) was the most frequently occurred 20ins subtype, followed by G778_P780dup (18/ 171, 10.5%). For the 19 patients treated with afatinib, they had a median PFS of 4.5 months and median OS of 11.5 months. The overall response rate in this cohort was 15.8% (3/19) and disease control rate was 68.4% (13/19). Next, we interrogated the clinical outcomes of specific 20ins subtype responding to afatinib. We found that patients harboring G778_P780dup (G778) achieved longer median PFS (10 vs 3.3 months, p¼0.32) and median OS (19.7 vs 7 months, p¼0.16) than non-G778 patients, consisting with in vitro results. Although statistical significance was not achieved due to limited number of G778_P780dup patients, this result warranted further investigation into this phenomenon. Moreover, to the best of our knowledge, we identified the first case of a lung squamous cell carcinoma patient harboring ERBB2 20ins from this cohort. He displayed favorable response to afatinib and achieved partial response with significant tumor shrinkage.
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Background: The MET pathway is frequently deregulated in human cancer, leading to dependency on MET signaling and hence this represents a potential therapeutic target in non-small cell lung cancer (NSCLC). MET alterations include MET exon 14-skipping mutations (METex14+) and MET amplification (METamp); these occur in w3% and 0.4e4% of NSCLCs, respectively. Tepotinib is a potent and highly selective, small molecule inhibitor of MET. Method: This single-arm, open-label, multicenter Phase 2 trial (NCT02864992) will assess the efficacy and safety of tepotinib, 500 mg once-daily as 1 st e3
rd line of treatment, in patients with histologically confirmed, Stage IIIB/IV NSCLC harboring either METex14+ (Cohort A, detected in tumor [TBx] and/or plasma [liquid biopsy; LBx] samples) or METamp (Cohort B). Patients with epidermal growth factor receptor (EGFR)-activating mutations or anaplastic lymphoma kinase (ALK) rearrangements are excluded. Enrollment into Cohort A began in September 2016 and recruitment into this cohort is ongoing. In Cohort B, patients will initially be enrolled based on METamp via LBx. The primary endpoint is objective response rate (ORR) assessed by an independent review committee (IRC) -via Response Evaluation Criteria in Solid Tumors version 1.1. Secondary endpoints include investigator-assessed ORR, and investigator/IRC-assessed duration of response, disease control, progression-free survival, and overall survival. The tolerability and safety of tepotinib will also be assessed as secondary objectives. Background: Human epidermal growth factor 2 (HER2, ERBB2) gene alterations have been identified as oncogenic drivers in 2-5% of lung cancers. ERBB2 In-frame insertions in exon 20 (20ins) lead to constitutive activation of receptor and downstream pathways. However, response heterogeneity of different exon 20 insertions to ERBB2 inhibitor afatinib exists. In vitro and structural modeling results suggested that Glycine778 may facilitate inhibitor binding to ERBB2. In this study, our aim was to improve our understanding of clinical characteristics in ERBB2-mutated Chinese lung cancer and investigate the clinical outcomes of specific ERBB2 exon 20 insertions in response to afatinib. Method: We reviewed 7520 lung cancer patients whose tissue or plasma biopsies were sequenced in a CLIA-certified sequencing laboratory between 2015 to 2018. Clinical records of 19 patients (18 adenocarcinomas and 1 squamous cell carcinoma) with several different ERBB2 20ins after afatinib treatment were collected for clinical outcomes evaluation. Results: ERBB2 20ins were identified in 2.27% (171/7,520) in this Chinese lung cancer cohort. It occurred with a high proportion in females with adenocarcinoma histology. 11.7% (20/171) ERBB2 20ins-positive patients harbored concomitant ERBB2 amplification. Y772_A775dup (119/171, 69.6%) was the most frequently occurred 20ins subtype, followed by G778_P780dup (18/ 171, 10.5%). For the 19 patients treated with afatinib, they had a median PFS of 4.5 months and median OS of 11.5 months. The overall response rate in this cohort was 15.8% (3/19) and disease control rate was 68.4% (13/19). Next, we interrogated the clinical outcomes of specific 20ins subtype responding to afatinib. We found that patients harboring G778_P780dup (G778) achieved longer median PFS (10 vs 3.3 months, p¼0.32) and median OS (19.7 vs 7 months, p¼0.16) than non-G778 patients, consisting with in vitro results. Although statistical significance was not achieved due to limited number of G778_P780dup patients, this result warranted further investigation into this phenomenon. Moreover, to the best of our knowledge, we identified the first case of a lung squamous cell carcinoma patient harboring ERBB2 20ins from this cohort. He displayed favorable response to afatinib and achieved partial response with significant tumor shrinkage. Background: Sintilimab, a novel full-humanized IgG 4 anti-PD-1 monoclonal antibody, showed its potent anti-tumor efficacy in preclinical models. Hence, we evaluated the efficacy and safety of sintilimab in combination with gemcitabine and cisplatin in treatment naïve advanced squamous cell non-small cell lung cancer (scNSCLC) patients in a multi-center phase Ib study in China (NCT02937116). Method: Histologically or cytologically confirmed locally advanced (stage IIIB), relapsed and metastatic (stage IV) scNSCLC patients who had not received any standard systemic treatment were recruited and received Sintilimab 200mg Q3W in combination with gemcitabine and cisplatin regimen, until disease progression or intolerant toxicity. Adverse events (AEs) were graded by NCI CTCAE v4.03. Tumor response was assessed by RECIST 1.1 and irRECIST every 9 weeks. Results: By August 1 st 2018, a total of 20 patients (19 males), with a median age of 65 years were enrolled in this study and received at least one dose of sintilimab. Nine patients were stage Ⅳ at baseline. The median treatment duration was 21.1 (0.1w34.3) weeks and median treatment cycle was 7.5 (1w12). Overall response rate was 64.7%, based on data of 17 patients who have received at least one radiological assessment. The other 6 patients had best response of stable disease. Both median progression free survival and duration of response were not reached. Treatment emergent adverse event (TEAE) occurred in all patients, 70% of which were grade 3 or over, but none of them were related to sintilimab. The most common treatment-related AEs were rash (3 patients) and fever (2 patients). Three patients experienced immunerelated AE, including 1 rash, 1 hyperthyroidism and 1 interstitial pneumonitis. Serious AE (SAEs) occurred in 8 patients, including 3 platelet count decrease, 1 neutrophil count decrease, 1 dysphagia, 1 pneumonia, 1 hydronephrosis and 1 interstitial pneumonitis. All SAEs were recovered or resolved after management except dysphagia. No AE leading to death occurred in this study. Conclusion: Sintilimab plus gemcitabine and cisplatin was generally safe and well tolerated in the study with a promising efficacy, suggesting that sintilimab may be a new solution for first line treatment of scNSCLC. A multi-center, double blind, randomized Phase III clinical trial with sintilimab is ongoing based on the evidence from current study. Keywords: safety, Sintilimab, squamous cell NSCLC, efficacy OA09 Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/KR, 6 Massachusetts General Hospital, Harvard Medical School, Boston, MA/US, 7 Anschutz Medical Campus, University of Colorado Denver, Aurora, CO/US, 8 TP Therapeutics, Inc., San Diego, CA/US Background: Patients (pts) with ROS1+ advanced NSCLC can be effectively treated with ROS1 tyrosine kinase inhibitors (TKIs). However, acquired resistance inevitably develops, resulting in disease relapse. Repotrectinib is a potent next-generation ROS1/TRK/ALK TKI, which inhibits ROS1 with a >90-fold greater potency (IC 50 <0.2 nM) than crizotinib. Preclinical studies demonstrate robust activity of repotrectinib against all known clinical ROS1 resistance mutations, including ROS1 G2032R resistance solvent-front mutation. Method: In this phase I study (NCT03093116), eligible adult pts with TKI-naïve or -pretreated advanced ALK/ROS1/TRK+ solid tumors received repotrectinib. Asymptomatic brain metastases were allowed. Primary objectives were to determine the MTD and RP2D of repotrectinib. Secondary objectives were to assess the safety, pharmacokinetics, and preliminary anti-tumor efficacy. This is a subgroup analysis of the ROS1+ NSCLC pts enrolled in the study. Results: As of July 13, 2018, 30 pts with advanced ROS1+ NSCLC have been treated at 5 dose levels, ranging from 40 to 240 mg/day and 160 mg twice a day; 10 were TKInaïve pts; 20 were TKI-refractory pts; and 16 had baseline CNS metastases. Based on Blinded Independent Central Review (BICR), 27 ROS1+ NSCLC pts were evaluable (10 TKI-naïve and 17 TKI-pretreated) and anti-tumor activity was observed at all dose levels. The confirmed objective response rate (ORR) was 80% in TKI-naïve pts, 18% in all TKI-pretreated pts, and 23% in patients with 1 prior TKI treatment. The intracranial confirmed ORR was 100% and 25% for TKI-naïve and TKI-pretreated pts, respectively. Tumor regressions were observed in 4 crizotinib-pretreated patients with a ROS1 G2032R solvent front resistance mutation, with 1 confirmed PR having a duration of response of 7.4 months dosed at 160 mg QD. A total of 72 pts has been treated in the ongoing TRIDENT-1 Phase 1 study and comprise the safety analysis group. Common (>10% of pts) treatment-related AEs included dizziness (50%), dysgeusia (46%), paresthesia (29%), constipation (19%), fatigue (18%), anemia (12.5 %) and nausea (11%). 4 DLTs were observed including 2 Grade 3 and 1 Grade 2 dizziness (at doses 240 mg QD and above) and 1 Grade 3 case of dyspnea and hypoxia. The MTD has not yet been reached. Conclusion: Repotrectinib is well tolerated and demonstrates promising activity in pts with advanced ROS1+ NSCLC, including those who failed prior TKI(s) or have tumors with solvent-front ROS1 resistance mutations. These phase 1 data warrant further clinical testing of repotrectinib in ROS1+ NSCLC. Keywords: G2032R, Mutation, resistance, ROS1
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